| Effect | Decrease |
| Values | Before/after for low-dose group: -34% ± 14% (SD). Before/after for high-dose group: -30% ± 11% (SD). No difference for placebo group. |
| Trial Design | Randomized trial |
| Trial Length | 2-4 Weeks |
| Number of Subjects | 16 |
| Sex | Male |
| Age Range | 18-29, 30-44 |
| Body Types | Overweight, Average |
This was a randomized cross-over study involving 16 recreationally active, nonsmoking adult males. Eight had asthma with exercise- and hyperpnea-induced bronchoconstriction (HIB), and eight didn’t. They were randomized to various combinations of high-dose (3.7 g EPA / 2.5 g DHA daily) or lower-dose (1.8 g EPA / 1.3 g DHA daily) fish oil, or placebo for 21 days. After 21 days, respiratory function was tested after a eucapnic voluntary hyperpnea (EVH) challenge, as well as several markers of airway inflammation.Funding issues for this study:
Overall, men with HIB saw similar improvements in the primary outcome of FEV1 after EVH challenge (-34% for the high-dose group, -30% for the low-dose group) with no change in the group without asthma and HIB. Markers of airway inflammation also improved to a roughly equal extent with both doses in men with asthma plus HIB.
Supplements & placebo (but not funding) provided by manufacturer (Croda)
